The AMZ2 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-mediated gene-disrupted population derived from the A-549 lung adenocarcinoma cell line. This polyclonal knockout pool targets the AMZ2 gene, encoding the alpha subunit of the mitochondrial processing peptidase (MPP). The editing strategy introduces loss-of-function alleles across the cell population, enabling investigation of AMZ2-dependent processes without clonal selection artifacts. This model is designed for functional genomics, drug screening, and mechanistic studies.
The host A-549 cell line is an adherent epithelial model established from a human lung adenocarcinoma in a 58-year-old Caucasian male. These cells exhibit a hypotriploid karyotype and are widely employed as an in vitro system for lung adenocarcinoma research, particularly for studying alveolar basal epithelial cell biology. A-549 cells retain oncogenic signaling and mitochondrial metabolic features of non-small cell lung cancer, making them a relevant platform for investigating mitochondrial proteostasis in the context of malignant transformation.
AMZ2 functions as the catalytic alpha subunit of MPP, which heterodimerizes with PMPCB to form the active peptidase that cleaves N-terminal targeting sequences from nuclear-encoded mitochondrial precursor proteins following their import through the TOM and TIM23 translocase complexes. This processing step is essential for the maturation and folding of mitochondrial proteins, including subunits of the respiratory chain and molecular chaperones such as HSP60 and HSP10. AMZ2 activity is regulated by mitochondrial stress signals and upstream transcription factors such as ATF5, CHOP, and PGC-1??, which coordinate the mitochondrial unfolded protein response. Downstream, AMZ2 modulates the functional integrity of mitochondrial chaperone networks and proteases like LONP1 and CLPP, thereby influencing mitochondrial quality control.
Disruption of AMZ2 in A-549 cells creates a valuable model to dissect the interplay between mitochondrial protein maturation and lung adenocarcinoma pathophysiology. Loss of MPP activity impairs mitochondrial precursor processing, leading to compromised respiratory chain assembly, altered metabolic flux, and sensitization to mitochondrial stress. This knockout model can be exploited to examine how mitochondrial dysfunction drives metabolic reprogramming in cancer, impacts apoptosis regulation, and contributes to tumor cell adaptation under nutrient deprivation. Furthermore, because AMZ2 is implicated in neurodegenerative and mitochondrial disorders, the A-549 background enables parallel studies of cancer-specific mitochondrial vulnerabilities and fundamental mechanisms of mitochondrial protein import.
Researchers can apply the AMZ2 knockout polyclonal cells to a range of experimental workflows, including mitochondrial import assays, Seahorse metabolic flux analysis, mitochondrial membrane potential measurements, and apoptosis assays. Co-immunoprecipitation combined with mass spectrometry-based proteomics facilitates the identification of AMZ2-interacting partners and substrates. These cells are also suited for drug screening campaigns targeting mitochondrial proteostasis modulators, as well as for mechanistic investigations into the mitochondrial unfolded protein response. Typical readouts include western blotting for precursor protein accumulation, RT-qPCR for stress-responsive gene expression, and immunofluorescence to assess mitochondrial morphology. For further technical information, please contact Ascent Research.
